הלוואות ואשראי לטווח ארוך של החברה: Scinai (SCNI)

Scinai Immunotherapeutics (SCNI) relies on its own Israeli CDMO plant equipped with bioreactors, ensuring production autonomy. The price indicator on the GURU.Markets platform chart demonstrates the asset's dynamics, where long-term debt stands at 0.00. The business focuses on R&D development of stable biologics against infections. Innovative NanoAb antibodies derived from alpaca cells enable the treatment of lungs via inhalation, replacing traditional injections.

Scinai Immunotherapeutics is developing an adaptive nanobody platform for the rapid creation of antiviral drugs. This indicator captures obligations with maturities exceeding one year, reflecting the business's long-term debt load. Investors assess this balance between financial stability and the cost of servicing borrowed capital. For an R&D company, such loans often fund the scaling of laboratory capacities. By analyzing the company's long-term debt structure, one can determine the company's margin of safety.